MeiraGTx Holdings plc (FRA:328)

Market Cap	515.57M +18.9%
Revenue (ttm)	23.37M +96.8%
Net Income	-143.77M
EPS	-1.80
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	21
Open	6.55
Previous Close	6.60
Day's Range	6.55 - 6.55
52-Week Range	4.02 - 7.90
Beta	n/a
RSI	45.49
Earnings Date	Mar 13, 2026

About MeiraGTx Holdings

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 409
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 328

Financial Performance

In 2024, MeiraGTx Holdings's revenue was $33.28 million, an increase of 137.42% compared to the previous year's $14.02 million. Losses were -$147.79 million, 75.9% more than in 2023.

Financial numbers in USD